Eur J Human Genet by Lehmann, K. et al.
ARTICLE
A novel R486Q mutation in BMPR1B resulting in
either a brachydactyly type C/symphalangism-like
phenotype or brachydactyly type A2
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Heterozygous missense mutations in the serine-threonine kinase receptor BMPR1B result typically in
brachydactyly type A2 (BDA2), whereas mutations in the corresponding ligand GDF5 cause brachydactyly
type C (BDC). Mutations in the GDF inhibitor Noggin (NOG) or activating mutations in GDF5 cause
proximal symphalangism (SYM1). Here, we describe a novel mutation in BMPR1B (R486Q) that is
associated with either BDA2 or a BDC/SYM1-like phenotype. Functional investigations of the R486Q
mutation were performed and compared with the previously reported BDA2-causing mutation R486W and
WT BMPR1B. Overexpression of the mutant receptors in chicken micromass cultures resulted in a
strong inhibition of chondrogenesis with the R486Q mutant, showing a stronger effect than the R486W
mutant. To investigate the consequences of the BMPR1B mutations on the intracellular signal
transduction, we used stably transfected C2C12 cells and measured the activity of SMAD-dependent
and SMAD-independent pathways. SMAD activation after stimulation with GDF5 was suppressed in
both mutants. Alkaline phosphatase induction showed an almost complete loss of activation by both
mutants. Our data extend the previously known mutational and phenotypic spectrum associated with
mutations in BMPR1B. Disturbances of NOG-GDF5-BMPR1B signaling cascade can result in similar
clinical manifestations depending on the quantitative effect and mode of action of the specific
mutations within the same functional pathway.
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Introduction
Isolated brachydactylies are a group of inherited hand and
foot malformations that are characterized by shortening of
the phalanges and/or metacarpal bones. Brachydactylies
usually follow an autosomal-dominant inheritance. In
1951, Julia Bell classified them clinically into five groups
(A–E) and three subgroups (A1–A3).1 In recent years,
some isolated brachydactylies have been characterized on a
molecular level providing new insight into the mechan-
isms of joint and digit development.2
Heterozygous missense mutations in bone morphoge-
netic protein receptor 1B (BMPR1B) were shown to cause
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brachydactyly type A2 (BDA2), a condition characterized
by brachymesophalangy of fingers II and V resulting in
shortening and medial deviation.3 Heterozygous carriers of
growth differentiation factor 5 (GDF5) loss-of-function
mutations are typically affected by brachydactyly type C
(BDC).4,5 The BDC phenotype includes brachymesopha-
langy of fingers II, III and V. Finger IV is usually unaffected
and thus appears as the longest finger of the hand.
Shortening of metacarpals I and hyperphalangy in fingers
II and III may occur and can be considered as relatively
characteristic signs. BDC can be highly variable ranging
from severely affected hands with very short fingers to
mildly affected cases with only moderate brachydactyly
most often affecting the middle and proximal phalanges of
fingers II and III. Typical features of BDA2 and BDC are
summarized in Table 1. Thus, brachydactylies C and A2 are
clearly distinct entities but have certain overlapping
features such as the hypoplasia of middle phalanges.
GDF5 and BMPR1B play an essential role in chondrocyte
differentiation and bone formation.6,7 As a secreted
protein, the ligand GDF5 binds to BMP receptors (BMPR
types 1 and 2) resulting in the activation of BMPR1B
by transphosphorylation through BMPR2. The transmem-
brane serine/threonine kinase receptor BMPR1B subse-
quently activates the SMAD-dependent pathway and/or
the p38 MAP kinase pathway. The oligomerization
mode of the BMP receptors at the cell surface determines
the activation of the different downstream pathways. The
formation of ligand-induced signaling complexes of
BMP receptors leads to the activation of the MAP kinase
pathway and, as a consequence, to the induction of
alkaline phosphatase (ALP). Ligand binding to already
preformed hetero-oligomeric BMP receptor complexes
stimulates the SMAD pathway. Both signal cascades
regulate the transcription of specific target genes that are
involved in bone formation.8 – 10
Extracellular inhibitors such as Noggin (NOG) prevent
BMP receptor activation by binding to GDFs and BMPs.
Inactivation of nog in the mouse results in a massive
overproduction of cartilage, whereas NOG mutations in
humans cause fusion of joints as observed in proximal
symphalangism (SYM1) and multiple synostosis syndrome.
Interestingly, a very similar phenotype can be caused
by mutations in GDF5 that result in an activation of
the protein through an alteration of the receptor binding
affinitiy.11
Here, we present a new mutation in BMPR1B (R486Q)
that is located in a highly conserved region of the receptor.
The mutation can either result in a typical BDA2 pheno-
type, or a combination of BDC and SYM1. Functional
assays demonstrate a strong inhibitory effect of this
mutation on chondrogenesis and a loss of intracellular
SMAD activation and induction of ALP.
Materials and methods
Case report of patients
(1) The proband, a 34-year-old German woman, presented
with isolated brachydactyly. Fingers II and III were severely
shortened and appeared slightly thinner than the others
(Figure 1a). The flexion of fingers I, IV and V was
unremarkable. Fingers II had only one interphalangeal
joint, and in fingers III the flexion was limited owing to
stiffened proximal interphalangeal joints (Figure 1b). All
fingernails were present. Hand radiographs (Figure 1c; left,
right) showed hypoplastic middle phalanges of fingers II
with a symphalangism between the proximal and middle
phalanx on the right hand (arrow in Figure 1, right).
Fingers III consisted of only two phalanges: the proximal
phalanges were abnormally formed and showed lateral
bowing and distal narrowing of both diaphyses. Within
these diaphyses, a dense line was visible (arrow in Figure 1,
left), possibly corresponding to a rudimentary joint or a
segmented epiphysis between the original proximal pha-
langes and the middle phalanges. Fingers I, IV, V,
metacarpal and carpal bones appeared normal. Overall,
the hand phenotype resembled BDC with additional
features of SYM1. A mild involvement of the feet with a
lateral deviation of the first and second toes, a slight
cutaneous syndactyly between the toes II and III, and a
moderate shortening of toes III to V with camptodactyly
was noted (Figure 1d). Body proportions, height, weight
Table 1 Clinical characteristics of BDC and BDA2
Hand phenotype BDC BDA2
Brachymesophalangy Hypoplastic middle phalanges of fingers
II, III and V with relative sparing of finger
IV
Hypoplastic/absent middle phalanges of
fingers II and occasionally V
Deviation of fingersa Ulnar deviation of fingers II and/or III Radial deviation of fingers II and V
Shortened metacarpals Usually shortened first metacarpal with
short thumb
No
Hyperphalangy or extra ossification centers
in phalangesa
Most commonly affecting fingers II and III No
BDA2, brachydactyly type A2; BDC, brachydactyly type C.
aFeatures not observed in all patients.
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and head circumference were normal. Neither of her
parents was affected.
(2) The affected boy is the first child of unrelated healthy
parents. After birth, an unusual bilateral shortening and
deviation of the index fingers with only one flexion crease
was noticed. The finger movements in all existing joints
were unremarkable. All fingernails were present. Radio-
graphs of the hands at the age of 26 months confirmed the
index fingers malformation with an absent middle phalanx
on the left and a very small middle phalanx on the
right side. In addition, the middle phalanges of fingers V
were hypoplastic. The feet showed slightly shortened
toes II. This clinical manifestation represents a typical
BDA2 phenotype.3 At 26 months of age, the patient’s
development was unremarkable and height, weight and
head circumference were normal. Neither of his parents
was affected.
Molecular testing
Genomic DNA was extracted from blood samples by
standard methods. The coding sequence, cds, (10 exons)
of BMPR1B was amplified by standard PCR protocols as
reported previously.3 The cds of GDF5, NOG and IHH was
also amplified and sequenced in a similar manner. Exact
PCR conditions are reported elsewhere (for GDF512; for
NOG13; for IHH14).
Micromass cultures
Micromass cultures from chicken limb buds were prepared
as described previously.11 Infection was performed with
1 ml of replication competent avian sarcoma (RCAS) viral
supernatants containing the cds encoding WT-chicken
Bmpr1b (WT-chBmpr1b) or R486W-chBmpr1b as described
previously.3 Additional in vitro mutagenesis was performed
to introduce the mutation R486Q into the WT-chBmpr1b
using the Quick Change site-directed Mutagenesis kit
(Stratagene, La Jolla, CA, USA). Culture medium (DMEM-
F12, 2% chicken serum, 4 mM L-glutamine, 1000 U/ml
penicillin and 100 mg/ml streptomycin) was replaced every
2 days. For each condition, four replicates were performed
in parallel. Micromass cultures were fixed and stained with
Alcian blue at days 5, 6 and 7. After 10 and 12 days in
culture, micromass cultures were fixed and detection of
ALP activity was achieved by incubation with NBT-BCIP.
Figure 1 Brachydactyly type C/symphalangism-like phenotype in patient 1. (a) Fingers II and III are shortened and (b) flexion was limited in fingers
II owing to stiffened proximal interphalangeal joints. (c, left, right) Radiographs: Note abnormally configurated proximal phalanges in both fingers III
with a dense line within the diaphyses possibly corresponding to a rudimentary joint (arrow left). Note synostosis between the proximal and middle
phalanx on the right finger II (arrow right). (d) The toes are mildly affected.
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Quantification of Alcian blue and ALP staining were
achieved by histomorphometric analyses using the Axio-
Vision software tool AutMess (Zeiss, Carl Zeiss MicroImaging
GmbH, Go¨ttingen).
Generation of C2C12 cells stably expressing WT
Bmpr1b, R486Q-Bmpr1b or R486W-Bmpr1b
Site-directed mutagenesis on the Bmpr1b-retroviral con-
struct (Bmpr1b-EGIRT) was performed using the Quick
Change site-directed Mutagenesis kit (Stratagene). C2C12
cells were transduced by infection with helper-free VSV-G-
pseudotyped retroviruses as described previously.15 Briefly,
293T cells were used as packaging cells and transfected with
the retroviral construct (carrying the Bmpr1b sequence)
and plasmids coding for gag-pol and VSV-G. Twenty-four
hours post-transfection, 293T cells were treated with 10 mM
sodium-butyrate for 10 h. C2C12 cells were infected with
retroviral supernatant 48 h and 72 h post-transfection.
Transduction efficiencies were controlled by GFP, which
was located on the same retroviral construct.
Expression of WT Bmpr1b, R486Q-Bmpr1b or R486W-
Bmpr1b was controlled by Western blotting using mono-
clonal mouse anti-HA antibody (7HA Sigma-Aldrich
Chemie gmbH, Taufkirchen). The HA epitope was inte-
grated at the N-terminus (extracellular) of each receptor.9
Luciferase reporter gene assay
C2C12 cells stably expressing WT Bmpr1b, R486Q-Bmpr1b
or R486W-Bmpr1b were transfected with BRE luciferase
reporter construct (p(BRE)4-luc),16 renilla luciferase
(pRLTK) (Promega GmbH, Mannheim) as an internal
control for transfection efficiency using Lipofectaminet
(Invitrogen GmbH, Karlsruhe, Germany). Cells were
starved for 5 h in DMEM containing 0.5% FCS and
stimulated for 16–24 h with increasing amounts of recom-
binant GDF5 under starving conditions. Cell lysis and
luciferase measurements were carried out according to
manufacturers’ instructions of the Dual Luciferase Assay
System (Promega) in triplicate. Luciferase activity was
recorded in relative light units by calculating the quotient
between firefly and renilla activity.
ALP assay
Quantitative ALP assays were performed as described
previously.11 C2C12 cells stably expressing WT Bmpr1b,
R486Q- or R486W-Bmpr1b were seeded at a density of
1104 cells/96-well plates in growth media (high-glucose
DMEM, 10% FCS and 2 mM L-glutamine in 10% CO2). After
24 h, stimulation with recombinant GDF5 was performed
in media with reduced FCS (high-glucose DMEM, 2% FCS
and 2 mM L-glutamine in 10% CO2) for 3 days. ALP activity
was measured in triplicate for C2C12 cells in 96-well plates
by lysing cells in ALP-buffer1 (0.1 M glycine, pH 9.6, 1%
Nonidet P-40, 1 mM MgCl2 and 1 mM ZnCl2). After the
addition of ALP substrate through 1 volume of ALP-buffer2
(5 mM p-nitrophenyl phosphate (p-NPP), 0.1 M glycine (pH
9.6), 1 mM MgCl2 and 1 mM ZnCl2), and subsequent
termination of the reaction by adding 0.25 volumes 2 M
NaOH ALP activity was calculated by the released amount
of p-NP from the substrate p-NPP, which was determined
spectrophotometrically at 405 nm.
Results and discussion
Identification of a R486Q mutation in BMPR1B that
results in a BDC/SYM1 phenotype or BDA2
As patient 1 showed phenotypic similarities with BDC and
SYM1, we first sequenced the coding region of GDF5 and
NOG, but no mutation was found. Subsequently, we
performed mutation screening in BMPR1B. We identified
a new c.1457G4A missense mutation which results in an
arginine to glutamine substitution at the position 486
(R486Q). This mutation is located in a highly conserved
region of BMPR1B within a C-terminal motif also termed
nonactivating-non-downregulating box. Previous work has
shown that this region is important for endocytosis of
the TGFb type 1 receptor and for the regulation of the
activation process by transphosphorylation between TGFb
receptors.17 Because of the similarities between the highly
homologous TGFb and BMP receptors, it is likely that
this region has a similar function in BMPR1B. The
identical mutation was also found in patient 2 who
showed, in contrast to patient 1, typical BDA2. A possible
modifying IHH mutation (causing brachydactyly type A1)
was excluded in both patients. The mutational screening
of the parents confirmed that both mutations had occurred
de novo.
The middle phalanges of fingers II were hypoplastic or
absent in both patients. However, the severe shortening
and abnormal configuration of finger III together with
symphalangism in patient 1 was not observed in case 2 and
are not part of the BDA2 spectrum. The more severe
phenotype in patient 1 could be owing to the stronger
functional effect of the R486Q mutation when compared
with the previously described BDA2-associated mutations
I200K and R486W. The phenotype in the investigated
patient group with these latter mutations shows only a
slight clinical variability. The clinical features seen in
patient 1, with BDC-similar phenotype and symphalan-
gism, has never been observed in these patients. The
clinical difference between cases 1 and 2 can only be
explained by phenotypic variability owing to unknown
modifiers and/or stochastic effects at present. Parts of the
observed phenotype in patient 1 have been described to
be caused by mutations in GDF5 (BDC) or NOG (SYM1).
The phenotypic overlap of case 1 with BDC and SYM1
reflects the interaction of the major players within the
BMP/GDF pathway, that is, the ligand (GDF5), its receptor
(BMPR1B) and the inhibitor (NOG). Furthermore, it
shows that mutations within one pathway can result in
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overlapping or even identical phenotypes, as recently
also demonstrated for activating mutations in GDF5 that
cause SYM1.11
Several in vitro and in vivo assays were performed
previously to investigate the functional consequences of
the I200K and R486W mutations in Bmpr1b.3 It was
demonstrated that the mutation I200K acts in a dominant-
negative manner potentially by a disturbance of the
proper transphosphorylation process between the BMP
receptors and the loss of Bmpr1b kinase function. In
contrast, the mutation at the highly conserved amino-acid
position 486 showed a normal kinase activity and thus
differs in its mode of action, but the exact functional
mechanism of the R486W mutation remained unclear. It is
conceivable that a special amino-acid change at such a
conserved region of presently unexplained function may
cause disturbances of protein–protein interactions be-
tween the BMP receptors and other molecules, or alters
the activity of the receptor itself. In addition, modifier
genes could have an important role concerning the severity
of the manifestation.
Functional analysis of Bmpr1b mutants in micromass
cultures indicates a stronger inhibiting effect on
chondrocyte differentiation by the R486Q mutant
than the R486W mutant
WT and mutant Bmpr1b cds constructs were expressed in
chicken limb micromass cultures using an RCAS virus. This
system is an in vitro model for chondrogenic differentia-
tion. Cell differentiation and cartilagenous matrix produc-
tion were measured by Alcian blue and ALP. We
investigated chondrogenesis induced by both mutants
(R486Q and R486W) in comparison to WT Bmpr1b. Cells
infected with WT Bmpr1b were not distinguishable from
non-infected control cultures. As demonstrated in Figure
2a and b, transfection with mutant Bmpr1b resulted in a
strong inhibition of cartilage differentiation at days 5, 6
and 7, whereas the R486Q mutant shows a stronger effect
than the R486W mutant. This result was also confirmed by
ALP staining of micromass cultures at days 10 and 12. As
shown in Figure 2c, uninfected control and WT Bmpr1b
cultures are clearly ALP positive, whereas cultures infected
with the mutant Bmpr1b showed only little induction of
ALP. Again, the R486Q mutation had a stronger effect than
the R486W mutant.
Bmpr1b mutations at the position 486 fail to induce
intracellular SMAD signaling
To identify possible functional differences between the two
Bmpr1b mutants and WT Bmpr1b, we treated C2C12 cells
stably expressing Bmpr1b (WT or mutant) with recombi-
nant GDF5. C2C12 cells are mesenchymal progenitor cells
that can differentiate into different cells (eg osteoblasts).
The binding of a ligand to preformed BMP receptor
complexes at the cell surface results in the phosphorylation
and activation of Bmpr1b, which in turn results in the
activation of the intracellular SMAD signaling cascade.9
To further characterize the functional effect caused by
the mutations, we used a C2C12 cell assay with a
Figure 2 Overexpression of Bmpr1b mutants in micromass
cultures. (a) Photographs of retroviral-infected micromass cultures
with RCAS containing either Bmpr1b or indicated mutants. Chondro-
genic differentiation was monitored after 5–7 days for proteoglycan
matrix production with Alcian blue staining, and after 10 and 12 days
for prehypertrophic differentiation with ALP staining. Uninfected
(control) and Bmpr1b-infected micromass cultures showed normal
chondrogenic differentiation as demonstrated by time-dependent
increase of proteoglycan matrix and ALP activity after 1 week in
culture. Cultures expressing either the R486Q or R486W mutation
exhibited a strong inhibition of chondrogenesis. (b) The quantification
of Alcian blue incorporation into the extracellular matrix of micromass
cultures is shown. (c) The quantification of ALP staining as a marker for
prehypertrophic differentiation is depicted. *Significant difference.
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SMAD-dependent reporter construct. The quantity of
measurable luciferase activity reflects the degree of acti-
vated SMAD signaling. In general, GDF5 has a very high
affinity to BMPR1B but only a minimal signal transduction
efficiency via other BMP receptors.19 As demonstrated in
Figure 3a, C2C12 cells stably transfected with WT Bmpr1b
showed a dose-dependent increase in GDF5-mediated
reporter gene activity. Saturation was reached at 500 pM.
Both mutants are not able to transduce SMAD activation
when treated with variable amounts of recombinant GDF5.
It seemed that the R486Q mutant had a stronger effect
than the R486W mutant. The control culture showed some
minimal luciferase activity. This effect can be explained by
minimal endogenous SMAD signaling activated by other
pathways.
Functional analysis of Bmpr1b mutants in C2C12 cells
demonstrates a complete loss of osteoblastic
differentiation
In this assay, the degree of ALP activity reflects the
activation of p38 MAP kinase signaling as the transcription
of the ALP gene depends mainly on this pathway. C2C12
cells do not express significant amounts of Bmpr1b and
therefore show no ALP activity when treated with GDF5.
Figure 3b illustrates a dose-dependent increase of ALP
induction upon GDF5 treatment in stably WT Bmpr1b-
expressing C2C12 cells with a saturation at about 10 nM.
The level of ALP activity corresponded to the GDF5
concentrations used for treatment up to 5 nM. Higher
GDF5 concentrations did not increase the ALP activity
presumably owing to saturation of the BMP receptors
capacity. The Bmpr1b mutations were tested with the same
dose range of recombinant GDF5. Both the R486Q and
R486W mutant showed no osteoblastic differentiation as
demonstrated by the lack of ALP activity under 2.5–30 nM
GDF5 concentrations. A quantitative difference between
the two mutants was not detectable.
Our results demonstrate that both BMPR1B mutations at
position 486 have a strong inhibitory effect on chondro-
genesis and osteoblastic differentiation and cause a
disturbance in the intracellular SMAD and MAP kinase
signaling. Our functional assays indicate a stronger effect
of the R486Q mutant when compared with the R486W
mutant. This may explain the phenotypic variability
observed in the two affected individuals described here.
Whereas patient 2 had classical BDA2, patient 1 showed a
combination of BDC and SYM1 and thus a more severe
phenotype. Neither of the latter phenotypes has previously
been observed in individuals with the R486W mutation,
indicating that the R486Q mutation shifts the spectrum
to the more severe side. Furthermore, SYM1 is not regarded
to be part of the BDC spectrum and has not been reported
in association with GDF5 loss-of-function mutations.
The occurrence of symphalangism caused by mutations
in the BMP inhibitor NOG suggests that an upregulation of
BMP signaling causes abnormal joint formation. In fact,
gain-of-function mutations in GDF5 cause SYM1 most
likely through the activation of the BMPR1A, the receptor
normally activated by BMP2.11 The association of sympha-
langism and BDC with the BMPR1B receptor mutation
Figure 3 Bmpr1b mutants do not transmit GDF5 signals via
SMAD-dependent and SMAD-independent pathways. (a) SMAD
activation. The relative luciferase activity reflects the degree of
activated SMAD signaling. Untransfected C2C12 cells were used as a
control. The minimal SMAD activity in the control culture and in the
unstimulated WT and mutant cultures is explainable by minimal
endogenous SMAD activation in this system. C2C12 cells transfected
with WT Bmpr1b showed a dose-dependent increase in GDF5-
mediated reporter gene activity. Bmpr1b R486Q and R486W mutants
lack the ability to activate Smads. (b) ALP activation. C2C12 were
treated with variable amounts of recombinant GDF5. Treatment with
GDF5 in cells expressing WT Bmpr1b results in a strong induction of
ALP which is a marker for osteoblastic differentiation mediated via the
p38/MAP kinase pathway. Cells expressing Bmpr1b mutants R486Q
and R486W display no ALP activity and show no difference to parental
C2C12 cells. (c) Expression of WT and mutant Bmpr1b in stable
transfected C2C12 cells. Western blotting was performed using anti-
HA (top) and anti-beta actin (bottom) antibodies on lysates of HA-
tagged Bmpr1b-transfected C2C12 cells to show equal expression
levels of Bmpr1b. Lane 1: C2C12 control, lane 2: WT Bmpr1b, lane 3:
R486W and lane 4: R486Q.
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R486Q suggests a twofold effect of this mutation. First, it
results in a partial inactivation of the GDF5 pathway
causing BDC. Second, the downregulation of BMPR1B
signaling leads to an relatively enhanced activation of
BMPR1A and thus BMP2 signaling which then causes
symphalangism similar to the GDF5 gain-of-function
mutations as shown in our previous work.11 Our observa-
tions indicate that hand disorders like BDC, BDA2 or SYM1
belong to a molecular disease family consisting of the
essential parts of the BMP pathway: the ligands, the
receptors and their inhibitors. Mutations in any of these
components may imitate phenotypes classically associated
with mutations in another component by dysregulating
the intricate equilibrium between them.
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